Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.
Devos T, Geukens T, Schauwvlieghe A, Ariën KK, Barbezange C, Cleeren M, Compernolle V, Dauby N, Desmecht D, Grimaldi D, Lambrecht BN, Luyten A, Maes P, Moutschen M, Romano M, Seyler L, Nevessignsky MT, Vandenberghe K, van Griensven J, Verbeke G, Vlieghe E, Yombi JC, Liesenborghs L, Verhamme P, Meyfroidt G. Devos T, et al. Among authors: meyfroidt g. Trials. 2020 Nov 27;21(1):981. doi: 10.1186/s13063-020-04876-0. Trials. 2020. PMID: 33246499 Free PMC article. Clinical Trial.
Correction to: A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.
Devos T, Geukens T, Schauwvlieghe A, Ariën KK, Barbezange C, Cleeren M, Compernolle V, Dauby N, Desmecht D, Grimaldi D, Lambrecht BN, Luyten A, Maes P, Moutschen M, Romano M, Seyler L, Nevessignsky MT, Vandenberghe K, van Griensven J, Verbeke G, Vlieghe E, Yombi JC, Liesenborghs L, Verhamme P, Meyfroidt G. Devos T, et al. Among authors: meyfroidt g. Trials. 2020 Dec 14;21(1):1024. doi: 10.1186/s13063-020-04947-2. Trials. 2020. PMID: 33317581 Free PMC article. No abstract available.
The role of organizational characteristics on the outcome of COVID-19 patients admitted to the ICU in Belgium.
Taccone FS, Van Goethem N, De Pauw R, Wittebole X, Blot K, Van Oyen H, Lernout T, Montourcy M, Meyfroidt G, Van Beckhoven D; Belgian Society of Intensive Care Medicine and the Belgian Collaborative Group on COVID-19 Hospital Surveillance. Taccone FS, et al. Among authors: meyfroidt g. Lancet Reg Health Eur. 2020 Dec 23;2:100019. doi: 10.1016/j.lanepe.2020.100019. eCollection 2021 Mar. Lancet Reg Health Eur. 2020. PMID: 35104305 Free PMC article.
Evaluation of drotrecogin alpha use in a Belgian university hospital.
Spriet I, Meersseman W, Wilmer A, Meyfroidt G, Casteels M, Willems L. Spriet I, et al. Among authors: meyfroidt g. Pharm World Sci. 2006 Oct;28(5):290-5. doi: 10.1007/s11096-006-9045-3. Epub 2006 Nov 17. Pharm World Sci. 2006. PMID: 17111246
Early versus late parenteral nutrition in critically ill adults.
Casaer MP, Mesotten D, Hermans G, Wouters PJ, Schetz M, Meyfroidt G, Van Cromphaut S, Ingels C, Meersseman P, Muller J, Vlasselaers D, Debaveye Y, Desmet L, Dubois J, Van Assche A, Vanderheyden S, Wilmer A, Van den Berghe G. Casaer MP, et al. Among authors: meyfroidt g. N Engl J Med. 2011 Aug 11;365(6):506-17. doi: 10.1056/NEJMoa1102662. Epub 2011 Jun 29. N Engl J Med. 2011. PMID: 21714640 Free article. Clinical Trial.
Intensive care unit acquired muscle weakness in COVID-19 patients.
Van Aerde N, Van den Berghe G, Wilmer A, Gosselink R, Hermans G; COVID-19 Consortium. Van Aerde N, et al. Intensive Care Med. 2020 Nov;46(11):2083-2085. doi: 10.1007/s00134-020-06244-7. Epub 2020 Sep 28. Intensive Care Med. 2020. PMID: 32986233 Free PMC article. No abstract available.
A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol.
Misset B, Hoste E, Donneau AF, Grimaldi D, Meyfroidt G, Moutschen M, Compernolle V, Gothot A, Desmecht D, Garigliany M, Najdovski T, Laterre PF. Misset B, et al. Among authors: meyfroidt g. BMC Pulm Med. 2020 Dec 7;20(1):317. doi: 10.1186/s12890-020-01361-x. BMC Pulm Med. 2020. PMID: 33287790 Free PMC article.
Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma.
Devos T, Van Thillo Q, Compernolle V, Najdovski T, Romano M, Dauby N, Jadot L, Leys M, Maillart E, Loof S, Seyler L, Moonen M, Moutschen M, Van Regenmortel N, Ariën KK, Barbezange C, Betrains A, Garigliany M, Engelen MM, Gyselinck I, Maes P, Schauwvlieghe A, Liesenborghs L, Belmans A, Verhamme P, Meyfroidt G; DAWn-plasma investigators. Devos T, et al. Among authors: meyfroidt g. Eur Respir J. 2022 Feb 10;59(2):2101724. doi: 10.1183/13993003.01724-2021. Print 2022 Feb. Eur Respir J. 2022. PMID: 34446469 Free PMC article. Clinical Trial.
202 results